Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors
DOI10.1016/J.JTBI.2022.111403OpenAlexW4313419761MaRDI QIDQ2684584FDOQ2684584
Authors: Daiki Tatematsu, Marwa Akao, Hyeongki Park, Shingo Iwami, Keisuke Ejima, Shoya Iwanami 
Publication date: 16 February 2023
Published in: Journal of Theoretical Biology (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1016/j.jtbi.2022.111403
Recommendations
- Improving precision and power in randomized trials for COVID‐19 treatments using covariate adjustment, for binary, ordinal, and time‐to‐event outcomes
- Simplified within-host and dose-response models of SARS-CoV-2
- Modeling the viral dynamics of SARS-CoV-2 infection
- Design of viral dynamic studies for efficiently assessing potency of anti-HIV therapies in AIDS clinical trials
- Time optimal control studies on COVID-19 incorporating adverse events of the antiviral drugs
Applications of statistics to biology and medical sciences; meta analysis (62P10) Epidemiology (92D30)
This page was built for publication: Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2684584)
